Selpercatinib: First Approval

State-of-the-Art Strategies for Targeting RET-Dependent Cancers

(2020) Vivek Subbiah et al.   JOURNAL OF CLINICAL ONCOLOGY

Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.

(2020) Vivek Subbiah et al.   JOURNAL OF CLINICAL ONCOLOGY

Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer.

(2020) Manisha H. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Selpercatinib (LOXO-292) in patients with RET-fusion+ non-small cell lung cancer.

(2020) Koichi Goto et al.   JOURNAL OF CLINICAL ONCOLOGY

First experience of LOXO-292 in the management of pediatric patients with RET-altered cancers.

(2019) Ulrike Gerdemann et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I study of LOXO-292, a highly selective RET inhibitor, in pediatric patients with RET-altered cancers.

(2019) Steven G. DuBois et al.   JOURNAL OF CLINICAL ONCOLOGY

Selective RET kinase inhibition for patients with RET-altered cancers

(2018) V Subbiah et al.   ANNALS OF ONCOLOGY

A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.

(2018) Alexander E. Drilon et al.   JOURNAL OF CLINICAL ONCOLOGY